(140 days)
Not Found
No
The device description and performance studies focus on a standard enzymatic assay and spectrophotometric measurement, with no mention of AI or ML techniques. The "Mentions AI, DNN, or ML" section explicitly states "Not Found".
No
Explanation: This device is an in vitro diagnostic (IVD) device used for the quantitative analysis of ethyl alcohol in human samples, intended for the diagnosis and treatment of alcohol intoxication and poisoning. It does not directly provide therapy.
Yes
The "Intended Use / Indications for Use" section explicitly states that the device is "an in vitro diagnostic device" and that "The measurement of ethanol is used for the diagnosis and treatment of alcohol intoxication and poisoning."
No
The device is an in vitro diagnostic assay that relies on chemical reactions and spectrophotometric measurements, indicating it is a reagent-based device with associated hardware (automated clinical chemistry analyzers), not a software-only device.
Yes, this device is an IVD (In Vitro Diagnostic).
The "Intended Use / Indications for Use" section explicitly states: "The Immunalysis Ethyl Alcohol Enzyme Assay is an in vitro diagnostic device for the quantitative analysis of ethyl alcohol (ethanol) in human urine, serum or plasma with automated clinical chemistry analyzers."
N/A
Intended Use / Indications for Use
The Immunalysis Ethyl Alcohol Enzyme Assay is an in vitro diagnostic device for the quantitative analysis of ethyl alcohol (ethanol) in human urine, serum or plasma with automated clinical chemistry analyzers. The measurement of ethanol is used for the diagnosis and treatment of alcohol intoxication and poisoning. This assay is calibrated against ethyl alcohol. This device is intended for prescription use only.
Product codes (comma separated list FDA assigned to the subject device)
DIC
Device Description
The Immunalysis Ethyl Alcohol Assay is based on the oxidation of ethyl alcohol to acetaldehyde by alcohol dehydrogenase (ADH) and nicotinamide adenine dinucleotide (NAD) reduced to NADH resulting in an absorbance change measured spectrophotometrically at 340nm. The concentration of ethanol in the sample is directly proportional to the ADH activity.
Mentions image processing
Not Found
Mentions AI, DNN, or ML
Not Found
Input Imaging Modality
Not Found
Anatomical Site
Not Found
Indicated Patient Age Range
Not Found
Intended User / Care Setting
For use in laboratories; intended for prescription use only.
Description of the training set, sample size, data source, and annotation protocol
Not Found
Description of the test set, sample size, data source, and annotation protocol
Not Found
Summary of Performance Studies (study type, sample size, AUC, MRMC, standalone performance, key results)
The following laboratory performance studies were performed to determine substantial equivalence of the Immunalysis Ethyl Alcohol Enzyme Assay to the predicate device. Assay performance was established using the Olympus AU400e analyzer.
-
Limit of Blank (LoB)/Limit of Detection (LoD)
- Sixty (60) blank measurements were taken from unaltered drug free negative human urine, serum and plasma to calculate Limit of blank (LoB).
- Four samples of each matrix containing concentrations in the range LoB to 4xLoB were tested in replicates of five on two reagent lots over three days to calculate Limit of Detection (LoD).
- LoB of the assay is 0.481 mg/dL for urine and 0.668 mg/dL for serum and 0.652 mg/dL for plasma.
- LoD of the assay is 1.3 mg/dL for urine, 1.7 mg/dL for serum and 1.7 mg/dL for plasma.
-
Limit of Quantitation (LoQ)
- Limit of Quantitation (LoQ) is selected at a level equal to or higher than LoD.
- Four independent samples of each matrix spiked at concentration of LoQ were tested on two reagent lots to verify LoQ.
- Results demonstrated that drug concentration equal to or above LoQ, 2.9 mg/dL, can be quantitatively determined with suitable accuracy.
-
Linearity/Recovery
- A linearity study in the quantitative mode was conducted by spiking a drug free urine, serum and plasma pool with a high concentration of EtOH at upper limit of claimed measuring range. Additional pools were made by serially diluting the high concentration specimen with drug free urine, serum and plasma to achieve concentrations ranging from 3 mg/dL to 600 mg/dL. The high value specimen was evaluated with the predicate device to determine initial high-level value. The 0 mg/dL specimen was made from drug free urine, serum and plasma. Each pool was tested in triplicate to calculate the mean concentration values that were used to calculated drug recovery.
- Linearity test results are presented in Table 1 to Table 3 for Urine, Serum, and Plasma respectively, showing high r² values (0.999 for all matrices), indicating good linearity.
-
Precision
- Precision study was performed for 20 days, 2 runs per day in duplicate on drug free urine, serum and plasma (N=80 for each matrix) spiked with EtOH to concentrations of 25 mg/dL, 75 mg/dL, 125 mg/dL, 150 mg/dL, 175 mg/dL and 200 mg/dL and calibrators and controls at concentrations of 50 mg/dL, 100 mg/dL and 300 mg/dL.
- The spiked concentrations were confirmed by Gas Chromatography - Flame Ionization Detector (GC-FID).
- The study established assay reproducibility and verified the precision performance in the claimed measuring range. Precision test results are presented in Table 4 to Table 6 for Urine, Serum, and Plasma respectively, showing low coefficient of variations (CV%).
-
Specificity and Cross-Reactivity
- Structurally and functionally similar compounds were spiked into drug free urine, serum and plasma at levels that will yield a result that is equivalent to the concentration of 10 mg/dL and 100 mg/dL.
- The study verified assay performance relative to the ability of the device to exclusively determine certain drugs, in quantitative mode. Cross-reactivity test results are presented in Table 7 to Table 9.
-
Interference – Structurally Unrelated Compounds in Urine
- Structurally unrelated compounds were evaluated in quantitative mode by spiking the potential interferent into drug free urine containing EtOH at 10 mg/dL and 100 mg/dL.
- All potential interferents analyzed verified that assay performance is unaffected by externally ingested compounds.
-
Interference - Endogenous Compounds and Urine Preservatives
- Endogenous compounds and urine preservatives were evaluated in quantitative mode by spiking the potential interferent into drug free urine containing EtOH at concentration of 10 mg/dL and 100 mg/dL.
- Assay performance is unaffected by all the internally existing physiological conditions tested.
-
Interference - Interferents in Serum and Plasma
- Potential interfering substances in serum and plasma matrices were evaluated in quantitative mode by spiking the compound into drug free serum and plasma containing EtOH at concentration of 10 mg/dL and 100 mg/dL, respectively.
- Additional anticoagulants were evaluated by spiking into drug free plasma containing EtOH at concentration of 10 mg/dL and 100 mg/dL.
- Assay performance is unaffected by all the internally existing physiological conditions tested.
-
Interference - pH
- To evaluate potential interference from the effect of urine pH, device performance in the quantitative mode was tested using a range of urine pH values. All test samples were prepared in drug-free urine containing EtOH at concentration of 10 mg/dL and 100 mg/dL.
- No interference was observed at urine pH values ranging from 3.0 to 11.0.
-
Interference - Specific Gravity
- To evaluate potential interference from the specific gravity of urine, device performance in the quantitative mode was tested using a range of physiologically relevant urine specific gravity values. All test samples were prepared in drug free urine containing EtOH at concentration of 10 mg/dL and 100 mg/dL.
- No interference was observed at urine specific gravity values ranging from 1.000 to 1.030.
-
Calibration Duration
- Drug free negative urine spiked with EtOH at concentration of 10 mg/dL, 100 mg/dL and 300 mg/dL were tested in quantitative mode at time points up to 14 days. At the initial time point, a two-point calibration curve was established. This calibration was used through the duration of this study. The test results met acceptance criteria at each time point.
- The recommended frequency of calibration is 14 days.
-
Specimen Stability
- Drug free negative urine, serum and plasma spiked with EtOH at concentration of 100 mg/dL and 300 mg/dL were stored in industry standard collection containers and tested by assay kit at each time point at 30°C and at 2°C - 8°C.
- Test results indicated that urine samples containing EtOH are stable for up to 14 days stored at ambient temperature up to 30℃, up to 6 months stored at 2°C - 8°C; serum samples containing EtOH are stable for up to 10 days stored at ambient temperature up to 30°C, up to 14 days stored at 2°C - 8°C; plasma samples containing EtOH are stable for up to 3 day stored at ambient temperature up to 30°C, up to 6 days stored at 2°C - 8°C.
-
Method Comparison
- Eighty (80) de-identified, unaltered leftover clinical urine samples, seventy-six (76) de-identified, unaltered leftover clinical serum samples and sixty-four (64) de-identified, unaltered leftover clinical plasma samples obtained from clinical testing laboratories were analyzed for EtOH with the Immunalysis Ethyl Alcohol Enzyme Assay in quantitative mode and compared to results of predicate device.
- The instruments used were an Olympus AU 400e.
- Method comparison test results are presented in Table 15, showing high correlation (r² values) between the candidate and predicate devices across all matrices (Urine: 0.9964, Serum: 0.9948, Plasma: 0.9932).
Key Metrics (Sensitivity, Specificity, PPV, NPV, etc.)
Not Found. Precision (SD, CV%), LoB, LoD, LoQ, Linearity (Slope, Intercept, r²), and Recovery (%) values are provided in the tables.
Predicate Device(s): If the device was cleared using the 510(k) pathway, identify the Predicate Device(s) K/DEN number used to claim substantial equivalence and list them here in a comma separated list exactly as they appear in the text. List the primary predicate first in the list.
Lin-Zhi Ethyl Alcohol Enzymatic Assay [K032461]
Reference Device(s): Identify the Reference Device(s) K/DEN number and list them here in a comma separated list exactly as they appear in the text.
Not Found
Predetermined Change Control Plan (PCCP) - All Relevant Information for the subject device only (e.g. presence / absence, what scope was granted / cleared under the PCCP, any restrictions, etc).
Not Found
§ 862.3040 Alcohol test system.
(a)
Identification. An alcohol test system is a device intented to measure alcohol (e.g., ethanol, methanol, isopropanol, etc.) in human body fluids (e.g., serum, whole blood, and urine). Measurements obtained by this device are used in the diagnosis and treatment of alcohol intoxication and poisoning.(b)
Classification. Class II.
0
Image /page/0/Picture/0 description: The image shows the logo of the U.S. Food and Drug Administration (FDA). The logo consists of two parts: the Department of Health & Human Services logo on the left and the FDA logo on the right. The FDA logo is in blue and includes the letters "FDA" followed by the words "U.S. FOOD & DRUG ADMINISTRATION" in a stacked format.
October 31, 2018
Immunalysis Corporation Wenying (Jessica) Zhu Regulatory Affairs Specialist III 829 Towne Center Drive Pomona, CA 91767
Re: K181553
Trade/Device Name: Immunalysis Ethyl Alcohol Enzyme Assay Regulation Number: 21 CFR 862.3040 Regulation Name: Alcohol test system Regulatory Class: Class II Product Code: DIC Dated: September 19, 2018 Received: September 20, 2018
Dear Wenying (Jessica) Zhu:
We have reviewed your Section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act) that do not require approval of a premarket approval application (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act. Although this letter refers to your product as a device, please be aware that some cleared products may instead be combination products. The 510(k) Premarket Notification Database located at https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfpmn/pmn.cfm identifies combination product submissions. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration. Please note: CDRH does not evaluate information related to contract liability warranties. We remind you, however, that device labeling must be truthful and not misleading.
If your device is classified (see above) into either class II (Special Controls) or class III (PMA), it may be subject to additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 898. In addition, FDA may publish further announcements concerning your device in the Federal Register.
Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. You must comply with all the Act's requirements, including, but not limited to: registration and listing (21 CFR Part 807); labeling (21 CFR Part
1
801 and Part 809); medical device reporting of medical device-related adverse events) (21 CFR 803) for devices or postmarketing safety reporting (21 CFR 4, Subpart B) for combination products (see https://www.fda.gov/CombinationProducts/GuidanceRegulatoryInformation/ucm597488.htm); good manufacturing practice requirements as set forth in the quality systems (OS) regulation (21 CFR Part 820) for devices or current good manufacturing practices (21 CFR 4, Subpart A) for combination products; and, if applicable, the electronic product radiation control provisions (Sections 531-542 of the Act); 21 CFR 1000-1050.
Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21 CFR Part 807.97). For questions regarding the reporting of adverse events under the MDR regulation (21 CFR Part 803), please go to http://www.fda.gov/MedicalDevices/Safety/ReportaProblem/default.htm.
For comprehensive regulatory information about medical devices and radiation-emitting products, including information about labeling regulations, please see Device Advice
(https://www.fda.gov/MedicalDevices/DeviceRegulationandGuidance/) and CDRH Learn (http://www.fda.gov/Training/CDRHLearn). Additionally, you may contact the Division of Industry and Consumer Education (DICE) to ask a question about a specific regulatory topic. See the DICE website (http://www.fda.gov/DICE) for more information or contact DICE by email (DICE@fda.hhs.gov) or phone (1-800-638-2041 or 301-796-7100).
Sincerely,
Kellie B. Kelm -S
for Courtney H. Lias, Ph.D. Director Division of Chemistry and Toxicology Devices Office of In Vitro Diagnostics and Radiological Health Center for Devices and Radiological Health
Enclosure
2
Indications for Use
510(k) Number (if known) K181553
Device Name Immunalysis Ethyl Alcohol Enzyme Assay
Indications for Use (Describe)
The Immunalysis Ethyl Alcohol Enzyme Assay is an in vitro diagnostic device for the quantitative analysis of ethyl alcohol (ethanol) in human urine, serum or plasma with automated clinical chemistry analyzers. The measurement of ethanol is used for the diagnosis and treatment of alcohol intoxication and poisoning. This assay is calibrated against ethyl alcohol. This device is intended for prescription use only.
Type of Use (Select one or both, as applicable)
| ☑ Prescription Use (Part 21 CFR 801 Subpart D) |
|---|
| ☐ Over-The-Counter Use (21 CFR 801 Subpart C) |
CONTINUE ON A SEPARATE PAGE IF NEEDED.
This section applies only to requirements of the Paperwork Reduction Act of 1995.
DO NOT SEND YOUR COMPLETED FORM TO THE PRA STAFF EMAIL ADDRESS BELOW.
The burden time for this collection of information is estimated to average 79 hours per response, including the time to review instructions, search existing data sources, gather and maintain the data needed and complete and review the collection of information. Send comments regarding this burden estimate or any other aspect of this information collection, including suggestions for reducing this burden, to:
Department of Health and Human Services Food and Drug Administration Office of Chief Information Officer Paperwork Reduction Act (PRA) Staff PRAStaff@fda.hhs.gov
"An agency may not conduct or sponsor, and a person is not required to respond to, a collection of information unless it displays a currently valid OMB number."
3
K181553 510(k) SUMMARY
A. GENERAL INFORMATION
| Applicant Name: | Immunalysis Corporation
829 Towne Center Drive
Pomona, CA 91767
Establishment # 2020952 |
|------------------|--------------------------------------------------------------------------------------------------------------------|
| Company Contact: | Wenying (Jessica) Zhu
Regulatory Affairs Specialist III
Phone: (909) 451-6697
Email: wzhu@immunalysis.com |
| Date Prepared: | September 19, 2018 |
B. DEVICE IDENTIFICATION
| Trade or Proprietary Names: | Immunalysis Ethyl Alcohol Enzyme Assay |
|---|---|
| Common Name: | Ethyl Alcohol Enzyme Assay |
C. REGULATORY INFORMATION
| Device Classification Name: | Alcohol Test System |
|---|---|
| Product Codes: | DIC |
| Regulatory Class: | II |
| Classification Regulation: | 21 CFR 862.3040, Alcohol Test System |
| Panel: | Toxicology (91) |
| Predicate Device: | Lin-Zhi Ethyl Alcohol Enzymatic Assay [K032461] |
D. DEVICE DESCRIPTION
The Immunalysis Ethyl Alcohol Assay is based on the oxidation of ethyl alcohol to acetaldehyde by alcohol dehydrogenase (ADH) and nicotinamide adenine dinucleotide (NAD) reduced to NADH resulting in an absorbance change measured spectrophotometrically at 340nm. The concentration of ethanol in the sample is directly proportional to the ADH activity.
E. INTENDED USE
The Immunalysis Ethyl Alcohol Enzyme Assay is an in vitro diagnostic device for the quantitative analysis of ethyl alcohol (ethanol) in human urine, serum or plasma with automated clinical chemistry analyzers. The measurement of ethanol is used for the diagnosis and treatment of alcohol intoxication and poisoning. This assay is calibrated against ethyl alcohol. This device is intended for prescription use only.
4
Image /page/4/Picture/0 description: The image shows the word "IMMUNALYSIS" in white letters on a red background. The background is shaped like a horizontal arrow. The word is written in all capital letters. The image is simple and clear.
| Attribute | Predicate Device
Lin-Zhi Ethyl Alcohol Enzymatic
Assay [K032461] | Candidate Device
Immunalysis Ethyl Alcohol Enzyme
Assay |
|-------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|---------------------------------------------------------------|
| Intended Use | For quantitative analyses of ethyl
alcohol in human urine, serum, or
plasma. | Same |
| Sample Matrix | Urine, serum or plasma | Same |
| Measured Analytes | Ethyl Alcohol (EtOH) | Same |
| Test Principle | Enzymatic assay | Same |
| User Environment | For use in laboratories | Same |
| Test Methodology | In the presence of nicotinamide
adenine dinucleotide (NAD), ADH
converts ethyl alcohol to
acetaldehyde and reduces NAD to
NADH. The ethyl alcohol
concentration is then directly
proportional to the ADH activity.
The enzyme activity is measured at
340 nm wavelength. | Same |
| Instrumentation | Performed on clinical chemistry
analyzers | Same |
| Reagent Storage | 2-8°C until expiration date | Same |
| Assay Range | 3-600 mg/dL | Same |
F. COMPARISON WITH PREDICATE
G. PERFORMANCE CHARACTERISTICS
The following laboratory performance studies were performed to determine substantial equivalence of the Immunalysis Ethyl Alcohol Enzyme Assay to the predicate device. Assay performance was established using the Olympus AU400e analyzer.
1. Limit of Blank (LoB)/Limit of Detection (LoD)
Sixty (60) blank measurements were taken from unaltered drug free negative human urine, serum and plasma to calculate Limit of blank (LoB). Four samples of each matrix containing concentrations in the range LoB to 4xLoB were tested in replicates of five on two reagent lots over three days to calculate Limit of Detection (LoD). LoB of the assay is 0.481 mg/dL for urine and 0.668 mg/dL for serum and 0.652 mg/dL for plasma. LoD of the assay is 1.3 mg/dL for urine, 1.7 mg/dL for serum and 1.7 mg/dL for plasma.
2. Limit of Quantitation (LoQ)
Limit of Quantitation (LoQ) is selected at a level equal to or higher than LoD. Four independent samples of each matrix spiked at concentration of LoQ were tested on two reagent lots to verify LoQ. Results demonstrated that drug concentration equal to or above LoQ, 2.9 mg/dL, can be quantitatively determined with suitable accuracy.
5
3. Linearity/Recovery
A linearity study in the quantitative mode was conducted by spiking a drug free urine, serum and plasma pool with a high concentration of EtOH at upper limit of claimed measuring range. Additional pools were made by serially diluting the high concentration specimen with drug free urine, serum and plasma to achieve concentrations ranging from 3 mg/dL to 600 mg/dL. The high value specimen was evaluated with the predicate device to determine initial high-level value. The 0 mg/dL specimen was made from drug free urine, serum and plasma. Each pool was tested in triplicate to calculate the mean concentration values that were used to calculated drug recovery. Linearity test results are presented in Table 1 to Table 3.
| Expected Concentration
(mg/dL) | Mean Observed
Concentration
(mg/dL) | Recovery (%) | |
|-----------------------------------|-------------------------------------------|--------------|--|
| 0.0 | 0.0 | N/A | |
| 3.0 | 3.1 | 102.2 | |
| 12.0 | 12.0 | 100.3 | |
| 72.0 | 73.9 | 102.6 | |
| 132.0 | 132.2 | 100.2 | |
| 192.0 | 195.4 | 101.8 | |
| 252.0 | 250.3 | 99.3 | |
| 312.0 | 308.0 | 98.7 | |
| 372.0 | 363.0 | 97.6 | |
| 432.0 | 421.3 | 97.5 | |
| 492.0 | 484.4 | 98.5 | |
| 552.0 | 565.8 | 102.5 | |
| Slope | | 0.996 | |
| Intercept | | -0.172 | |
| r2 | | 0.999 | |
Table 1. Linearity/Recovery Test Results - Urine
Table 2. Linearity/Recovery Test Results - Serum
| Expected Concentration
(mg/dL) | Mean Observed
Concentration
(mg/dL) | Recovery (%) |
|-----------------------------------|-------------------------------------------|--------------|
| 0.0 | 0.0 | N/A |
| 3.0 | 3.0 | 101.1 |
| 23.2 | 23.1 | 99.4 |
| 83.2 | 87.2 | 104.8 |
| 143.2 | 146.1 | 102.0 |
| 203.2 | 199.8 | 98.3 |
| 263.2 | 262.2 | 99.6 |
| 323.2 | 317.8 | 98.3 |
| 383.2 | 385.9 | 100.7 |
6
Image /page/6/Picture/0 description: The image shows the word "IMMUNALYSIS" in white letters on a red background. The background is shaped like a horizontal arrow. The word is written in all capital letters and is centered on the arrow. The arrow is pointing to the right.
| Expected Concentration
(mg/dL) | Mean Observed
Concentration
(mg/dL) | Recovery (%) |
|-----------------------------------|-------------------------------------------|--------------|
| 443.2 | 441.4 | 99.6 |
| 503.2 | 493.6 | 98.1 |
| 563.2 | 544.3 | 96.6 |
| Slope | 0.978 | |
| Intercept | 2.869 | |
| r² | 0.999 | |
Table 3. Linearity/Recovery Test Results - Plasma
| Expected Concentration
(mg/dL) | Mean Observed
Concentration
(mg/dL) | Recovery (%) |
|-----------------------------------|-------------------------------------------|--------------|
| 0.0 | 0.0 | N/A |
| 3.0 | 3.0 | 98.9 |
| 9.9 | 10.5 | 106.1 |
| 69.9 | 69.7 | 99.8 |
| 129.9 | 127.5 | 98.2 |
| 189.9 | 188.4 | 99.2 |
| 249.9 | 242.3 | 96.9 |
| 309.9 | 299.9 | 96.8 |
| 369.9 | 351.9 | 95.1 |
| 429.9 | 410.0 | 95.4 |
| 489.9 | 470.4 | 96.0 |
| 549.9 | 547.0 | 99.5 |
| Slope | 0.970 | |
| Intercept | 0.307 | |
| r2 | 0.999 | |
4. Precision
Precision study was performed for 20 days, 2 runs per day in duplicate on drug free urine, serum and plasma (N=80 for each matrix) spiked with EtOH to concentrations of 25 mg/dL, 75 mg/dL, 125 mg/dL, 150 mg/dL, 175 mg/dL and 200 mg/dL and calibrators and controls at concentrations of 50 mg/dL, 100 mg/dL and 300 mg/dL. The spiked concentrations were confirmed by Gas Chromatography - Flame Ionization Detector (GC-FID). The study established assay reproducibility and verified the precision performance in the claimed measuring range. Precision test results are presented in Table 4 to Table 6.
7
Image /page/7/Picture/0 description: The image shows the word "IMMUNALYSIS" in white letters on a red background. The word is written in all capital letters and is centered in the image. The background is a solid red color, and the letters are a bright white color. The image is simple and easy to read.
| Concentration
(mg/dL) | # of
Sample | Mean
Conc.
(mg/dL) | Repeatability | | Between Run | | Within-
Laboratory | |
|--------------------------|----------------|--------------------------|---------------|-----|-------------|-----|-----------------------|-----|
| | Sample | (mg/dL) | SD | CV% | SD | CV% | SD | CV% |
| 0 | 80 | 0.0 | 0.1 | N/A | 0.0 | N/A | 0.1 | N/A |
| 25 | 80 | 24.5 | 0.3 | 1.2 | 0.3 | 1.1 | 0.5 | 1.8 |
| 50 | 80 | 49.0 | 0.4 | 0.9 | 0.6 | 1.2 | 0.8 | 1.5 |
| 75 | 80 | 74.0 | 0.7 | 0.9 | 1.0 | 1.3 | 1.1 | 1.5 |
| 100 | 80 | 99.6 | 0.8 | 0.8 | 1.6 | 1.6 | 1.6 | 1.6 |
| 125 | 80 | 121.3 | 1.2 | 1.0 | 1.5 | 1.2 | 1.8 | 1.5 |
| 150 | 80 | 146.1 | 1.3 | 0.9 | 1.9 | 1.3 | 2.4 | 1.7 |
| 175 | 80 | 169.1 | 1.4 | 0.9 | 2.0 | 1.1 | 2.7 | 1.6 |
| 200 | 80 | 193.9 | 1.8 | 0.9 | 2.6 | 1.3 | 3.4 | 1.7 |
| 300 | 80 | 292.0 | 2.2 | 0.8 | 3.8 | 1.3 | 4.6 | 1.6 |
Table 4. Precision - Urine
Table 5. Precision – Serum
| Concentration
(mg/dL) | # of
Sample | Mean
Conc.
(mg/dL) | Repeatability | | Between Run | | Within-
Laboratory | |
|--------------------------|----------------|--------------------------|---------------|-----|-------------|-----|-----------------------|-----|
| | | | SD | CV% | SD | CV% | SD | CV% |
| 0 | 80 | 0.4 | 0.2 | N/A | 0.1 | N/A | 0.2 | N/A |
| 25 | 80 | 25.8 | 0.2 | 0.9 | 0.5 | 2.0 | 0.8 | 3.2 |
| 50 | 80 | 49.3 | 0.3 | 0.7 | 1.0 | 2.0 | 1.0 | 2.0 |
| 75 | 80 | 75.7 | 0.4 | 0.5 | 1.4 | 1.8 | 2.2 | 3.0 |
| 100 | 80 | 99.6 | 0.5 | 0.5 | 2.0 | 2.1 | 2.1 | 2.1 |
| 125 | 80 | 125.9 | 0.8 | 0.6 | 2.4 | 1.9 | 3.9 | 3.1 |
| 150 | 80 | 148.4 | 1.0 | 0.6 | 2.6 | 1.7 | 3.8 | 2.6 |
| 175 | 80 | 172.3 | 1.0 | 0.6 | 3.1 | 1.8 | 5.1 | 3.0 |
| 200 | 80 | 195.2 | 1.3 | 0.7 | 3.4 | 1.8 | 4.9 | 2.5 |
| 300 | 80 | 290.4 | 1.4 | 0.5 | 5.5 | 1.9 | 6.0 | 2.1 |
Table 6. Precision - Plasma
| Concentration
(mg/dL) | # of
Sample | Mean
Conc.
(mg/dL) | Repeatability | | Between Run | | Within-
Laboratory | |
|--------------------------|----------------|--------------------------|---------------|-----|-------------|-----|-----------------------|-----|
| | | | SD | CV% | SD | CV% | SD | CV% |
| 0 | 80 | 0.2 | 0.1 | N/A | 0.1 | N/A | 0.1 | N/A |
| 25 | 80 | 24.3 | 0.2 | 0.7 | 0.2 | 1.0 | 1.2 | 4.9 |
| 50 | 80 | 49.9 | 0.3 | 0.6 | 0.5 | 0.9 | 0.7 | 1.5 |
| 75 | 80 | 69.8 | 0.4 | 0.5 | 0.7 | 1.0 | 1.8 | 2.6 |
8
Image /page/8/Picture/0 description: The image shows the word "IMMUNALYSIS" in white letters on a red background. The background is shaped like a horizontal hexagon. The text is centered in the hexagon. The font is sans-serif and bold.
| Concentration
(mg/dL) | # of
Sample | Mean
Conc.
(mg/dL) | Repeatability | | Between Run | | Within-
Laboratory | |
|--------------------------|----------------|--------------------------|---------------|-----|-------------|-----|-----------------------|-----|
| 100 | 80 | 100.5 | 0.5 | 0.5 | 1.0 | 1.0 | 1.6 | 1.6 |
| 125 | 80 | 118.3 | 0.6 | 0.5 | 1.0 | 0.9 | 2.7 | 2.2 |
| 150 | 80 | 155.8 | 0.9 | 0.6 | 1.2 | 0.8 | 4.1 | 2.6 |
| 175 | 80 | 170.6 | 0.9 | 0.5 | 1.5 | 0.9 | 3.2 | 1.9 |
| 200 | 80 | 197.6 | 1.1 | 0.6 | 1.4 | 0.7 | 3.9 | 2.0 |
| 300 | 80 | 292.7 | 2.0 | 0.7 | 2.7 | 0.9 | 5.2 | 1.8 |
5. Specificity and Cross-Reactivity
Structurally and functionally similar compounds were spiked into drug free urine, serum and plasma at levels that will yield a result that is equivalent to the concentration of 10 mg/dL and 100 mg/dL. The study verified assay performance relative to the ability of the device to exclusively determine certain drugs, in quantitative mode. Cross-reactivity test results are presented in Table 7 to Table 9.
Table 7. Cross-Reactivity - Urine
| 10 mg/dL | 100 mg/dL | |||
|---|---|---|---|---|
| Compound | Compound Conc. | |||
| (mg/dL) | Cross-Reactivity | |||
| (%) | Compound Conc. | |||
| (mg/dL) | Cross-Reactivity | |||
| (%) | ||||
| Lot #1 | ||||
| Acetaldehyde | 3,000 |